+44 (0)1865 852 700
- Optimize your assays using recombinant antibodies selected for desired affinity
- Take a look inside Bio-Rad’s custom recombinant antibody facility. Learn from our antibody experts how your requirements for specialized anti-biotherapeutic antibodies can become a reality through the use of HuCAL technology.
Watch an interview recorded at the EBF 8th Open Meeting with R&D Manager Christian Frisch, where he explains how we use HuCAL® recombinant antibody technology to make anti-idiotypic antibodies for therapeutic drug monitoring.
Watch an interview with Michael Schwenkert on Anti-idiotypic antibodies and CAR-T cell therapies
Watch an interview with Michael Schwenkert on best practices for the characterization and quality control of anti-idiotypic antibodies for bioanalysis
Watch an interview recorded at EBF with Michael Schwenkert on how Bio-Rad makes neo-epitope specific antibodies against drug-target complexes, the challenges of bioanalytical assays in relation to antibody reagents, and how Bio-Rad is helping to advance the field of drug discovery and development.
Watch an interview recorded at EBF 2019 with Ulrich Mayer (Technical Sales Specialist), in which Mayer discusses Bio-Rad’s custom recombinant antibody generation capabilities and explains why global biopharmaceutical companies and CROs choose Bio-Rad for the generation of custom antibodies targeting different types of large molecule drugs and CAR-T cell therapies.
Bio-Rad is an expert manufacturer and supplier of antibodies for drug discovery, biosimilar and biobetter development, clinical diagnostics and academic research.
For biosimilar developers and CROs providing large molecule bioanalytical services our ready-made anti-biotherapeutic antibodies are ideally suited for highly specific and sensitive PK and ADA assays and cell-based neutralization assays. Our industry leading range offers antibodies against 14 marketed monoclonal antibody drugs, including rituximab, infliximab, adalimumab, trastuzumab and bevacizumab.
For innovator and biobetter drug discovery, preclinical research and clinical development, no other company can rival our unique custom recombinant monoclonal antibody service that generates highly specific, high affinity antibodies with greater than 90% success rates in only 8 weeks. We use a synthetic, fully human library of 45 billion antibodies coupled with a novel and improved form of phage display technology to select antibodies to the most challenging antigens, such as anti-idiotypic antibodies and antibody-target complexes, with simultaneous subtraction of unwanted specificities. Such antibodies are difficult to develop using traditional animal immunization methods.
Whether you need a ready-made product, a custom antibody generation project, or small to bulk manufacturing and purification services, we cater for all. We aim to help you reach your goals by providing the antibodies you need and a professional, long-term partnership for success.
For more information please click here
To contact us please click here